Expanding Treatment Options: Ceftobiprole Against Multidrug-Resistant Infections

Authors

  • Arwa Jabeen Jinnah Sindh Medical University Author
  • Abiha Fatima Jinnah Sindh Medical University Author
  • Abeera Saleem Mughal Jinnah Sindh Medical University Author

DOI:

https://doi.org/10.63501/ntga6364

Keywords:

Ceftobiprole, Antimicrobial resistance, Multidrug-resistant pathogens

References

1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet. 2022 Feb 12;399(10325):629-55. https://pubmed.ncbi.nlm.nih.gov/35065702/

2. Meštrović T, Haller S, Robles Aguilar G, Meinen A, Gershberg Hayoon A, Geffers C, Dörre A, Abu Sin M, Gray AP, Swetschinski LR, Ikuta KS. Antimicrobial resistance burden landscape in Germany in 2019: a comparative country-level estimation. JAC-Antimicrobial Resistance. 2025 Aug;7(4):dlaf142. https://pubmed.ncbi.nlm.nih.gov/40823668/

3. US Food and Drug Administration. FDA approves new antibiotic for three different uses [Internet]. 2024 https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses

4. El Solh AA. Ceftobiprole: a new broad spectrum cephalosporin. Expert opinion on pharmacotherapy. 2009 Jul 1;10(10):1675-86. https://pubmed.ncbi.nlm.nih.gov/19527192/

Downloads

Published

2025-10-14

Issue

Vol. 1 No. 9 (2025)

Section

⁠Letters to the Editor

Most read articles by the same author(s)